Quince Therapeutics, Inc.
QNCX$23M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSOUTH SAN FRANCISCO36 employees
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Nov 30, 2026
40wMarket Overview
Stock performance and key metrics
QNCX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
EryDex Low dose DSP
Nervous System Disease
Dexamethasone sodium phosphate
Ataxia Telangiectasia
Dex 21-P
Ulcerative Colitis
Dexamethasone
Nervous System Disorder
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
EryDex Low dose DSP | Phase 3 | Nervous System Disease | - |
Dexamethasone sodium phosphate | Phase 3 | Ataxia Telangiectasia | - |
Dex 21-P | Phase 2 | Ulcerative Colitis | - |
Dexamethasone | Phase 2 | Nervous System Disorder | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply